Copyright
©The Author(s) 2018.
World J Gastroenterol. Jul 7, 2018; 24(25): 2673-2685
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2673
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2673
Therapeutic agent | Active compound | Mode of action | Ref. |
Aminosalicylates (ASA) | 5-ASA | Decreases MPO activity, inhibits β-catenin activation | [23] |
Inhibits the generation and activity of IL-1β, IL-4, IL-5, IL-8, granulocyte-macrophage colony stimulating factor, and TNF-α | |||
Corticosteroids | Corticosteroids | [24] | |
Immunosuppressants | Azathioprine | Clinical remission | [25] |
6-mercaptopurine | Mucosal healing | ||
Cyclosporine A | |||
Tacrolimus | |||
Methotrexaten | |||
Antibiotics | Metronidazole | Decrease disease activity index | [26] |
Ciprofloxacin | Maintain remission | ||
Biological therapy | Infliximab | Neutralizes TNF-α | [27] |
Adalimumab | Reduces inflammation | ||
Certolizumab |
- Citation: Mijan MA, Lim BO. Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. World J Gastroenterol 2018; 24(25): 2673-2685
- URL: https://www.wjgnet.com/1007-9327/full/v24/i25/2673.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i25.2673